Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Šatný

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Vnitrni Lekarstvi|March 20, 2021
Fixed-dose combination of rosuvastatin and ezetimibeMartin Šatný
Vnitrni Lekarstvi|October 12, 2023
Dyslipidemia - the known unknownMartin Šatný
Current Atherosclerosis Reports|March 25, 2022
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive CardiologyTereza Altschmiedová, Veronika Todorovová, Michaela Šnejdrlová, et al.
Plos One|May 22, 2023
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemiasMichal Vrablík, Ivana Šarkanová, Katarína Breciková, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Vnitrni Lekarstvi|March 20, 2021
Fixed-dose combination of rosuvastatin and ezetimibeMartin Šatný
Vnitrni Lekarstvi|October 12, 2023
Dyslipidemia - the known unknownMartin Šatný
Current Atherosclerosis Reports|March 25, 2022
PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive CardiologyTereza Altschmiedová, Veronika Todorovová, Michaela Šnejdrlová, et al.
Plos One|May 22, 2023
Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemiasMichal Vrablík, Ivana Šarkanová, Katarína Breciková, et al.
Pageof 1